Weight loss & metabolic health
GLP-1 medications, insulin resistance, PCOS and metabolic health after 40 - what the evidence says about treatment fit, trade-offs, and realistic expectations.
Start here
GLP-1 medications
- Tirzepatide vs Semaglutide After MenopauseTirzepatide vs semaglutide after menopause should be framed around direct obesity-trial evidence and individual eligibility, not a blanket winner. Tirzepatide produced more average weight loss than injectable semaglutide in a 72-week head-to-head obesity trial, but the study was not designed around menopause. For a midlife woman, the right comparison is not just which drug lowers weight more. It is whether her body mass index, metabolic risk, contraindications, side-effect tolerance, cost, and maintenance plan make either prescription route appropriate. [1]
- Menopause Weight Loss: What Actually Changes After 45Menopause weight loss is harder to manage well when the only metric is scale weight. Study of Women's Health Across the Nation body-composition data suggest that around the menopause transition, fat gain accelerates and lean mass declines, even when total weight does not show the whole change. [1] The practical plan after 45 should check waist, three-month blood sugar marker, blood pressure, lipids, sleep apnea, medications, thyroid status when indicated, protein intake, resistance training, bone risk, constipation, glucagon-like peptide-1 eligibility, and maintenance. The goal is not simply "lose weight." It is to reduce cardiometabolic risk while protecting muscle, bone, function, and long-term follow-up.
- GLP-1 Eligibility After MenopauseGlucagon-like peptide-1 eligibility after menopause starts with labeled body mass index and weight-related condition criteria, but it does not end there. Current Wegovy labeling includes chronic weight management for adults with obesity or overweight plus a weight-related comorbidity, cardiovascular event-risk reduction in adults with established cardiovascular disease and obesity or overweight, and noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. [1] Current Zepbound labeling includes chronic weight management and moderate to severe obstructive sleep apnea in adults with obesity. [2] A good screen also reviews contraindications, severe gastrointestinal disease, gallbladder and pancreatitis history, kidney/dehydration risk, medications, pregnancy plans, lean mass, bone risk, and follow-up capacity.
Common questions
Why measure waist after menopause?
In Study of Women's Health Across the Nation Heart, visceral fat rose 8.2% per year in the 2 years before the final menstrual period and 5.8% per year after it, even after body mass index was considered.
Did tirzepatide beat semaglutide in a head-to-head weight-loss trial?
Yes. SURMOUNT-5 randomized 751 adults with obesity but without diabetes. At week 72, mean weight change was -20.2% with tirzepatide and -13.7% with injectable semaglutide. Waist change was -18.4 cm with tirzepatide and -13.0 cm with semaglutide.
Why is weight loss harder after menopause?
Menopause can coincide with more central fat, less lean mass, sleep disruption, insulin resistance, medication changes, pain, lower training volume, and lower energy expenditure. The scale alone may miss the body composition shift.
What body mass index usually qualifies for glucagon-like peptide-1 weight-loss care?
Current Wegovy and Zepbound labels include adults with obesity, or adults with overweight and at least one weight-related condition. The clinician still has to review safety and fit.